Epidemiology studies show that consumption of certain naturally occurring chemicals (generally plant-derived) can protect against the development of cancer (chemoprevention).
Introduction
There is increasing interest in trying to prevent cancer through the administration (usually oral) of a chemical or chemicals that are found in the natural environment (cancer chemoprevention) 1 ; 2 . Resveratrol, a phytoalexin found in many human consumables such as grapes and red wine 3 shows promise as an agent of this type.
A number of heterocyclic amines (HCAs) are formed during the routine cooking of red meat and meat containing products 4 , therefore populations who consume high levels of red meat are potentially exposed to HCAs. To date, all of the food-derived HCAs that have been examined have been shown to be carcinogenic in rodents 5 . In humans, the association between red meat intake and cancer, specifically cancer of the breast and colon, is well established and has been reported in many food-related case-control studies 6 ; 7 ; 8 . It has been shown that metabolic activation of the food-derived HCA pro-mutagens is via the oxidation of the exocyclic amine group by cytochrome P450 (CYP) 1A family enzymes 9 ; 10 ; 11 ; 12 . This is followed by subsequent phase II metabolism, by enzymes such as Nacetyltransferase 13 . Both of these metabolic steps are carried out with greater efficiency in human hepatic tissue than that of mice and rats 14 .
The most abundant HCA formed in cooked beef is PhIP 15 , thus humans are exposed to higher levels of this than any other HCA. PhIP is mutagenic and has been shown to induce mutations in both the lacZ transgene of Muta TM Mouse 16 and the lacI transgene from the intestine of BigBlue mice 17 . Of the several types of mutation found in these models, GCTA transversions were the most abundant and a significant number of -1 guanine frameshifts were also noted. Many of these mutations occurred at 5'-GGA-3' motifs. This pattern of mutation is very similar to that found in vitro 18 .
It has previously been demonstrated by our group and others that resveratrol aglycone can inhibit chemical-induced mutation in both bacterial and mammalian cells 19 ; 20 . Whether resveratrol can exert similar activity in vivo is not clear, however, studies suggest there are potential beneficial effects of resveratrol consumption. For example it has been shown that 0.01% resveratrol aglycone in the drinking water of Apc min mice (genetically predisposed to develop intestinal tumours) for 7 weeks decreased the formation of tumours in the small and large intestine by up to 70% 21 , while in another study, administration of resveratrol aglycone (200 g/kg/day) in drinking water to azoxymethane-treated male F344 rats for 100 days decreased the formation of aberrant crypt foci in the colon 22 . These studies therefore suggest that resveratrol has anti-mutagenic and anti-carcinogenic potential in vivo.
In the current study, the mouse model Muta TM Mouse was used to test the hypothesis that resveratrol aglycone has anti-mutagenic effects in vivo, using the food-borne carcinogen PhIP as a model food-derived genotoxicant. The Muta TM Mouse model employs a bacterial LacZ gene as a reporter for mutation. These reporter genes have been integrated into the mouse chromosome, which can be recovered as phage particles. We report that treatment of Muta™Mouse with resveratrol aglycone attenuates the colonic mutagenicity of PhIP and that there is a pronounced sex difference in both the mutagenic response to PhIP and its inhibition by resveratrol. prepared from a single colony on a freshly streaked plate, was grown overnight in an orbital incubator at 37°C, 200rpm, with LB broth (20g LB mix dissolved in 1L deionised water, sterilised by autoclaving), 0.2% maltose, 0.1mg/ml ampicillin and 0.02mg/ml Kanamycin.
Material and Methods

Chemicals
The following morning a 'day culture' was prepared from 1-2% of the 'overnight culture' in fresh LB broth and 0.2% maltose. After the bacterial cells had reached an OD 600 1.0, they were pelleted and resuspended in fresh LB broth containing 10mM MgSO 4 to give an OD 600 2.0. The cells were kept on ice until needed.
DNA packing and mutant selection
Shuttle vectors (gt10lacZ) were rescued from the genomic DNA of the liver and colon and single copies packaged into bacterial phage particles, using Transpak (Stratagene) packing extract following the manufacturer's instructions. One vial of Transpak packing extract (10µl) was used for each DNA sample. The extract was kept on dry ice (-40°C) until needed. The contents of the tube were quickly thawed before use. Using a wide-bore pipette tip, 5-10µl of genomic DNA (0.5-1mg/ml) was added to the thawed Transpack packing extract. The DNA-Transpack packing extract mixture was then incubated at 30°C for 90 min. After this, a further 12µl of Transpack packing extract was added to each sample and incubated for a further 90 min at 30°C. After this, 500µl of sterile SM buffer (1M Tris.HCL pH 7.5, 10mM MgSO 4 , 100mM NaCl, 0.01% gelatin) was added to each packaging reaction and vortexed.
The packaged phage were used to infect a culture of E. Coli (LacZ,GalE Non-mutants produced dark blue plaques. The mutation frequency for each sample of DNA was calculated as described by Dean and Myhr 24 .
Ethoxyresorufin O-demethylase activity.
CD2F1 mice were given resveratrol (10, 100, 1000 µg/kg in 50 µl DMSO/H 2 O 1:1 v/v) by oral gavage (po). DMSO:water vehicle (1:1/50 µl) was used as a vehicle control.
Half of the animals were dosed once a day until day five, and killed by cervical dislocation 24h after the last dose. The remaining animals continued to be dosed until day ten and killed on day eleven. The liver was removed from each animal, visually examined, weighed and hepatic microsomes prepared and stored as previously described 9 . The ethoxyresorufin O-deethylase (EROD) assay was used to determine CYP1A activity 11 . The formation of fluorescent resorufin was measured using a Shimadzu RF 540 Spectrofluorimeter with excitation at 535nm and emission at 585nm. Under these conditions, formation of resorufin is linear for at least 15 min and the fluorescence is proportional to the metabolic activity of the CYP enzymes.
Statistical analysis
Statistical analysis was performed using ANOVA with Tukey or Dunnet's post-test.
Results
The effect of resveratrol on PhIP-induced mutation in Muta
TM
Mouse
The transgenic mouse model, Muta TM Mouse, was used to assess the anti-mutagenic activity of resveratrol following co-treatment with the food carcinogen PhIP. To check for overt signs of treatment related toxicity, observations were made on all animals prior to dosing and 0.5h and 2h after dosing. No distress was noted to any animal and every treatment was well tolerated. The colon and liver from 6 animals (3 male and 3 female) from each treatment group were analysed for mutation frequency (MF) at the LacZ transgene (Tables 2   and 3 ).
The colon of ENU treated positive control mice contained a large number of mutated transgenes (1646  350 and 1047 ± 168 10 -6 (mean ± SD) plaque forming units (pfu) for male and female, respectively) ( Table 2 ). In contrast the DMSO:H 2 O negative control had a much lower colonic mutation frequency (127 ± 20 and 90 ± 436 (mean ± SD) plaque forming units (pfu) for male and female respectively), (Table 2) . ENU was also mutagenic to the liver, (321 ± 95 and 297 ± 177 x10 -6 (mean ± SD) plaque forming units (pfu) for male and female, respectively), but much reduced compared to the colonic mutation frequency (Tables 2 and 3 ). Similarly, the DMSO:H 2 O negative control also had a reduced hepatic mutation frequency (70 ± 12 and 46 ± 4 (mean ± SD) plaque forming units (pfu) for male and female respectively), (Table 3) . Thus for both male and females, ENU was a much less potent mutagen in the liver compared to the colon.
Resveratrol (1mg/kg) administration did not significantly alter the MF in the colon (125  22 and 84 ± 26 10 -6 pfu for male and female, respectively) or in the liver when compared to the DMSO:H 2 O vehicle control (Tables 2 and 3 ).
Treatment with 20 mg/kg PhIP significantly (p<0.001) increased the MF in the colon both in male and female mice compared to the vehicle control group (Table 2) . Moreover, the MF induced in the colon was 42.6% lower in female compared to male PhIP-treated mice (Table 2 ). Co-treatment of resveratrol with PhIP significantly reduced the PhIP-induced MF in the colon by ~35% in males (P<0.001; Table 2 ), however, the same comparison in females showed only a reduction of approximately 9% (Table 2 ). In the liver of treated males, the PhIP mutation frequency was elevated compared to the male vehicle controls, but this was not statistically significant and there was no effect of resveratrol on hepatic PhIP mutation frequency (Table 3 ). In females, neither PhIP, nor resveratrol nor PhIP plus resveratrol had any statistically significant effect on the hepatic mutation frequency (Table 3) .
Effect of resveratrol treatment on Ethoxyresorufin O-demethylase activity.
CD2F1 mice (genetically similar to Muta TM Mouse) that were treated daily with up to 1000µg/kg resveratrol for 5 days (group 1) or 10 days (group 2) did not show any overt signs of stress and the compound did not induce mortality or morbidity during the experimental period. Macroscopic observation of gastrointestinal and hepatic tissue did not reveal any gross sign of inflammation or abnormality in any treatment group. The average weight of each mouse in all treatment groups (1:1 DMSO:H2O control, 10 μg/kg resveratrol, 100 μg/kg resveratrol, 1000 μg/ kg resveratrol) was not significantly different before or after treatment (data not shown).
The effect of resveratrol treatment on hepatic microsomal EROD activity is presented in Figure 1 . EROD activity was inhibited by greater than 50% following 5 days treatment with 1000 µg/kg resveratrol, and more than 40% and 95% after 10 days treatment with 100
and 1000 µg/kg respectively, when compared to the DMSO:H 2 O control. Indeed, the fact that EROD activity is almost completely lost after 10 days treatment with 1000 µg/kg resveratrol is remarkable in view of the lack of any signs of liver toxicity in the mice. The dose-dependent decrease in EROD (CYP1A activity) supports the suggestion that resveratrol or its metabolites inhibit CYP1A activity in vivo.
Discussion
Transgenic mouse models containing recoverable bacterial reporter genes for measurement of in vivo mutation, such as Muta TM Mouse, are helpful for identifying mutagenic chemicals. In the current study, treatment of male and female Muta TM Mouse mice with resveratrol (1 mg/kg, once daily for 10 days) was well tolerated and did not cause any outward distress to either sex of animal. Furthermore, despite the reputed ability of resveratrol to accumulate within selected tissues in the body, especially the liver 25 , there was no evidence of macro-toxicity to the mice after dissection and macroscopic observation of the tissues (gastrointestinal tract, liver, lungs, heart, and kidneys). These observations looked for tissue swelling, abnormal growths, ulcerated tissue and inflammation. 16 it has previously been suggested that a longer exposure time to the HCA can increase the mutagenic effect in the lacZ and lacI transgenes 16 ; 17 and direct comparisons are difficult since the experimental protocols were different. It is important to note that the apparent tissue selectivity of PhIP-induced mutation (colon > liver) is consistent with PhIP's reported carcinogenicity; i.e. as an intestinal rather than hepatic carcinogen 14 .
We have previously demonstrated the anti-mutagenic effect of resveratrol following
PhIP treatment in vitro 20 and the current study shows that this effect also occurs in vivo in
Muta™Mouse. There have been no reports to date suggesting that resveratrol itself is mutagenic in the colon, and the data presented here confirm this.
When male and female mice were analysed separately it was observed that PhIP induced approximately 50% more mutation in the colon in males compared to females. A significant decrease in colon MF (~35% reduction) was observed for male mice following cotreatment with resveratrol and PhIP compared to PhIP alone, but the effect was much less in females (9% reduction). It is also worth noting that treatment with ENU induced a higher MF in male animals compared to females. Consistent with the present study, difference between the genders in the mutagenic potential of ENU and the heterocyclic amines have been previously reported 16 ; 28 ; 29 30 . The reason for this difference is not known, but is likely to be multifactorial and include differences in metabolism, (rate of activation versus rate of deactivation), toxicokinetics and the ability to repair DNA damage. It is also noteworthy that PhIP like resveratrol has been shown to act as a potent oestrogen 31 and as such might be expected to affect the genders differently. The potential of this latter activity to affect mutation and cancer has previously been reported 32 .
In the current study, 1 mg/kg resveratrol, the dose used to treat the mice in vivo, was found to be well tolerated with no obvious clinical signs of toxicity. This is consistent with a number of other in vivo rodent studies that observed biological effects at resveratrol concentrations equal to or less than this dose 22 . The doses of resveratrol employed here have been reported to be representative of concentrations that could occur through the consumption of red wine or red grapes 33 . It should be noted that the natural occurrence of resveratrol is as glycosides. Roches-Ribalta et al 34 have characterised the pharmacokinetics of resveratrol metabolites in humans after consumption of red wine and grape extract and report extensive metabolism with tissue and gut microbial involvement leading to a rapid appearance of plasma resveratrol glucuronide and sulphate conjugates.
It has been shown that multiple dosing of Muta™Mouse with PhIP is effective for genotoxicity 16 and in support of this, data presented here show that multiple daily doses of 20mg/kg PhIP produce an effective genotoxic response in the colon of Muta TM Mouse.
Resveratrol treatment did reduce PhIP-induced mutation in the colon of Muta TM Mouse, significantly so in the colon of male animals, possibly by reducing bioactivation of PhIP through inhibition of CYP activity 20 . In support of this mechanism, we examined the effect of resveratrol treatment on the hepatic drug metabolism activity (EROD) of CD2F1 mice (genetically similar to Muta TM Mouse). Resveratrol treatment (100 and 1000µg/kg) inhibited EROD activity (a marker for CYP1A activity), and this effect was potentiated following a longer exposure (10 days of resveratrol treatment). In support of this, in vitro studies have
shown that resveratrol can inhibit CYP1A1 with low affinity (IC50=1.2mM) 35 , which we have confirmed in CDF1 mouse microsomal preparations (data not shown). Clearly, attenuation of this enzyme activity could influence activation of PhIP, whose genotoxicity is CYP1A-mediated. In this context, it is important to note that our analysis of metabolic activity was determined 1 day after the last dose of resveratrol but analysis of mutagenic Moreover, PhIP like resveratrol has been shown to act as a potent oestrogen 31 and as such might be expected to affect the genders differently.
Our results show that resveratrol has anti-mutagenic properties in vivo in
Muta™Mouse, which appears to be more potent in males than females, possibly through inhibition of CYP enzymes. These data support the proposal that resveratrol has potential as a chemopreventive agent.
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Tables
Results are the mean ± SD of 5 individual mice per dose. All assays were performed in triplicate and were analysed for statistical significance. * P<0.01 compared to respective DMSO control (one way-ANOVA with Dunnett's post test).
